 | |
| Names | |
|---|---|
| Preferred IUPAC name 4-(Pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider |
|
| ECHA InfoCard | 100.054.393 |
| UNII | |
| |
| |
| Properties | |
| C17H25NO4 | |
| Molar mass | 307.38 g/mol |
| Pharmacology | |
| C04AX20 (WHO) | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Buflomedil, sold under the brand nameLoftyl, is avasoactive drug used to treatclaudication or the symptoms ofperipheral arterial disease. It is currently not approved by theFood and Drug Administration (FDA) for use in the United States.
This drug has been suspended from marketing in the European Union, because of concerns about severeneurological andcardiac toxicity.[1][2] In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options". The European Commission advised all member states to revoke marketing authorisation.[3]
Variousadverse effects have been reported to the FDA.[4]
Acylation between 1,3,5-trimethoxybenzene [621-23-8] (1) and 4-pyrrolidinobutyronitrile [35543-25-0] (2) occurs in chlorobenzene solvent in the presence of gaseous hydrochloric acid to giveBufomedil (3). This is a demonstration of theHoesch reaction.
